Longeveron's ELPIS II Trial Misses Primary Endpoint; Company Launches Strategic Review
LGVN sits 41% above its 52-week low of $4.75.
Summary
Longeveron's Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome failed its primary endpoint, with no significant improvement in right ventricular ejection fraction at 12 months (p=0.8336). The company is now exploring all options to maximize shareholder value, including engaging an investment bank and implementing cost containment. This is a major setback for the lead pediatric program, though the company highlights exploratory signals like fewer MACE events and no deaths in the treated arm. With a market cap around $21 million and cash runway only into Q4 2026, the strategic review signals potential restructuring or sale. Investors should watch for FDA discussions and any strategic transaction announcements.
At the time of this announcement, LGVN was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $4.75 to $12.30. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.